PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 25, 2026JAMA Neurology2 citations

Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease

View Full Paper
MMMarine Boudot de la MotteAGA. GavoilleCPCaroline Papeix

Key Points

  • The research aims to evaluate the safety of treatment discontinuation in patients with MOGAD.
  • Conducted observational study on adult patients with MOGAD
  • Monitored disease reactivation post-treatment discontinuation
  • Found low risk of disease reactivation after treatment discontinuation
  • Indicates potential for selected patients to stop treatment safely

Abstract

The low risk of disease reactivation found in this study suggests that discontinuing treatment may be considered in selected adult patients with MOGAD. Future clinical trials are necessary to confirm these results and establish guidelines in this situation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Motte et al. (2026) studied this question.

synapsesocial.com/papers/69c37b11b34aaaeb1a67d1bahttps://doi.org/10.1001/jamaneurol.2026.0268
Ask AI
Helpful
Bookmark
Share
View Full Paper